ABBV - AbbVie Inc.
| Previous Close | 91.91 |
| Open | 91.82 |
| Bid | 91.14 x 1300 |
| Ask | 91.17 x 1300 |
| Day's Range | 90.85 - 92.20 |
| 52 Week Range | 85.24 - 125.86 |
| Volume | 748,522 |
| Avg. Volume | 5,687,389 |
| Market Cap | 138.48B |
| Beta (3Y Monthly) | 1.47 |
| PE Ratio (TTM) | 22.70 |
| EPS (TTM) | 4.03 |
| Earnings Date | Nov 2, 2018 |
| Forward Dividend & Yield | 3.84 (4.23%) |
| Ex-Dividend Date | 2018-10-12 |
| 1y Target Est | 109.83 |
- PR Newswire•4 hours ago
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment - The submission is based on positive results ...
- Reuters•8 hours ago
Samsung launches third rival to AbbVie's Humira drug in EU
LONDON (Reuters) - South Korea's Samsung Bioepis and its partner Biogen (BIIB.O) have launched a third rival to AbbVie's (ABBV.N) blockbuster medicine Humira in Europe, ramping up competition for a slice ...
- Reuters•8 hours ago
Samsung launches third rival to AbbVie's Humira drug in EU
South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales. A fourth so-called biosimilar copy of Humira is expected soon from Mylan . The primary European patent on Humira expired on Oct. 16, opening the door to cheaper near-identical copies for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.
- The Wall Street Journal•13 hours ago
[$$] By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S.
Cheaper copies of the world’s biggest-selling drug will roll out across Europe this week after a key European patent for Humira expires Tuesday, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug. The reason: a formidable wall of patents built up by Humira-maker AbbVie Inc., that prevents the developers of “biosimilar” versions launching their products in the U.S. Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells in a process that resembles brewing.
- Business Wire•16 hours ago
The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV)
Law Offices of Howard G. Smith reminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) securities between October 25, 2013 and September 18, 2018, inclusive (the “Class Period”). AbbVie investors have until November 20, 2018 to file a lead plaintiff motion.
- Bloomberg•22 hours ago
Drug-Price Transparency Won’t End the Patent Games
The settlement will enable Sandoz to bring a generic version — called a biosimilar — to the U.S. market at the beginning of 2023, while paying AbbVie a royalty. This mirrored similar settlements with Mylan NV, Amgen Inc. and Samsung Bioepis Co. Ltd. that will allow all of them to sell generic Humira at staggered dates in 2023.
- PR Newswire•23 hours ago
AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018
- Eleven presentations of HUMIRA® (adalimumab) and pipeline data showcase breadth and depth of robust gastroenterology portfolio - First presentation of efficacy and safety results from the Phase 2b U-ACHIEVE ...
- Reuters•yesterday
Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU
Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.
Market Realist•yesterdayHow Analysts View Merck Stock, Pre-Q3 Results
Between October 11 and 12, Merck (MRK) stock rose ~2.11% from $68.37 to close at $69.81. It was 32% higher than its 52-week low of $52.83 on April 3. Merck’s 52-week high is $72.89, reached on October 10.
- The Wall Street Journal•yesterday
[$$] The Strategies AbbVie Employed to Protect Humira From Copycats
Inc.’s strategy to obtain dozens of U.S. patents to shield its top-selling drug, Humira, from copycat competition. AbbVie sued Boehringer Ingelheim in federal court in Delaware in 2017, alleging that the privately held, Germany-based company’s planned biosimilar version of Humira would infringe on many of AbbVie’s patents. Boehringer Ingelheim countered in a court filing last year that AbbVie has “engaged in a pattern of pursuing numerous overlapping and non-inventive patents for the purpose of developing a ‘patent thicket,’ using the patenting process itself as a means to seek to delay competition against its expensive and lucrative” Humira.
- ACCESSWIRE•2 days ago
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 15, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before November 20, 2018.
- ACCESSWIRE•2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Pomerantz LLP announces that a class action lawsuit hasbeen filed against AbbVie Inc. ("AbbVie" or the "Company") (ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- GlobeNewswire•2 days ago
CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Oct. 15, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
Market Realist•2 days agoMerck Is Expected to Record Steady Revenue Growth in Q3
Merck has announced it will be presenting its third-quarter revenue and earnings results on October 25. Analysts expect Merck to report revenue of $10.9 billion, primarily supported by Keytruda label expansions, Bridion, and its vaccine portfolio.
- GlobeNewswire•2 days ago
AbbVie Inc. Investor Alert: Law Offices of Andrew J. Brown Investigates Possible Breaches of Fiduciary Duty by Officers and Directors
Nationally recognized securities attorney Andrew J. Brown, founder of The Law Offices of Andrew J. Brown, announces an investigation into legal claims against the officers and Board of Directors of AbbVie (ABBV). When this news was revealed to the market, the Company's stock price dropped significantly.
- CNW Group•2 days ago
Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed
MONTREAL , Oct. 15, 2018 /CNW/ - AbbVie (ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved a label update for HUMIRA® (adalimumab) to include clinical and postmarketing safety data surrounding pregnancy and breastfeeding. "While Abbvie continues to exercise appropriate due caution regarding the safety of its products, the recent label change for HUMIRA is reassuring for women living with inflammatory bowel disease (IBD), particularly because IBD most commonly affects individuals in their peak reproductive years," said Dr. Cynthia Seow , Associate Professor, Division of Gastroenterology and Hepatology, University of Calgary .
- GlobeNewswire•3 days ago
SHAREHOLDER ALERT: QRTEA TRCO PVG USAT COCP TGTX ABBV CPB CHGG ACHC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Oct. 14, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•5 days ago
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 12, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before November 20, 2018.
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV
NEW YORK, NY / ACCESSWIRE / October 12, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the "Class Period").
GuruFocus.com•5 days agoAbbVie Permits US Sale of Sandoz's Humira Biosimilar
The license will take effect on Sept. 30, 2023
- GlobeNewswire•5 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LOGM, USAT, ABBV and ALNY
NEW YORK, Oct. 12, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•5 days ago
AbbVie Losses Alert: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important November 20, 2018 lead plaintiff deadline in the shareholder class action lawsuit against AbbVie Inc. (“AbbVie” or the “Company”) (ABBV). The lawsuit seeks to recover damages on behalf of those who purchased the securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the “Class Period”). If you purchased AbbVie securities, and/or would like to discuss your legal rights and options, please visit AbbVie Shareholder Class Action Lawsuit or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.
- Zacks•5 days ago
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
- GlobeNewswire•5 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AbbVie securities between October 25, 2013 and September 18, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/abbv. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
